Well Done LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Well Done LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4	Closed	-$1K	–	638
2018 Q4	$1K	Buy	+4	New	+$693	﹤0.01%	741

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Well Done LLC's VRTX Position: Q1 2019 in Review

Well Done LLC sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 4 shares — an estimated $1K sold.

Well Done LLC first reported a position in VRTX in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

Well Done LLC reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Well Done LLC sold 4 Vertex Pharmaceuticals shares in Q1 2019, an estimated $1K.
Well Done LLC first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Well Done LLC's Vertex Pharmaceuticals position peaked at $1K in Q4 2018.
736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Well Done LLC's 13F filing for Q1 2019, filed 9 May 2019.